Steakholder Foods Ltd. — Form 6-K Summary
Business context and reporting period
Steakholder Foods Ltd. furnished this Form 6-K on April 24, 2023, reporting an April 20, 2023 board approval of Chief Executive Officer Arik Kaufman’s employment terms. The filing is a corporate governance disclosure and does not report quarterly or annual financial results.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes and employment terms
- The compensation committee recommended, and the board approved, Mr. Kaufman’s employment terms as CEO.
- The approval followed the general meeting vote on March 30, 2023 and was made pursuant to the approval mechanism under the Israeli Companies Law, 5759-1999.
- The filing references employment terms described in the proxy statement furnished as Exhibit 99.1 to the company’s February 22, 2023 Form 6-K, but does not reproduce the compensation amounts or other detailed terms.
- The board and compensation committee stated that the proposed terms were at or below the average compensation for CEOs of peer companies, based on an independent benchmark commissioned by the company.
Management commentary, risks, and unusual items
- The board and compensation committee cited the risk of paying noncompetitive compensation to key personnel and the importance of maintaining stable management.
- The approval was made notwithstanding the resolution of the March 30, 2023 general meeting, as permitted under the cited Israeli Companies Law mechanism.
- The filing is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Important facts for investors to verify
- Review the February 22, 2023 Form 6-K and attached proxy statement for the precise CEO salary, bonuses, equity awards, benefits, term, severance, and other employment conditions.
- Verify the results and implications of the March 30, 2023 general meeting vote.
- Assess the potential dilution, cash cost, and accounting impact of any equity-based or incentive compensation included in the approved terms.